GO
Loading...

Vertex Pharmaceuticals Inc

More

  • Halftime Report: Stress Tests, Who's Making The Grade? Tuesday, 28 Apr 2009 | 1:11 PM ET

    Stocks traded only modestly lower Tuesday, despite concerns that if major banks need to raise more money a financial hurricane may be brewing.

  • Lightning Round: Cisco, US Steel and More Monday, 6 Apr 2009 | 8:26 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • The "Big Bank Theory" Of Picking Stocks Thursday, 12 Feb 2009 | 1:33 PM ET

    CNBC's "Power Lunch" team asked some of the best and the brightest from America's big financial firms to list the most promising stocks. Strategists from Citigroup, Goldman Sachs, Cowen & Co. and Deutsche Bank offered CNBC their stock picks.

  • A Tale Of Two Industries Tuesday, 13 Jan 2009 | 12:25 PM ET
    Jamie Dimon

    During his lunchtime keynote speech here at the JPMorgan Healthcare Conference JPM Chairman and CEO Jamie Dimon was asked to give his worst-case scenario for the economy. He said that'd be a 1982-type recession lasting about two years and with unemployment "North of 10 percent." Dimon said it would be "Irrational to not be prepared for that."

  • '09 Sector To Watch: Biotech Monday, 5 Jan 2009 | 6:06 PM ET

    Will M&A activity boost biotech stocks in 2009?

  • Vertex's $75,000 Question Friday, 19 Dec 2008 | 3:14 PM ET

    Drug pricing pressure under a Democratic administration be darned. $75,000. That's not a salary figure. That's the price one biotech analyst says Vertex Pharmaceuticals and its partner Johnson & Johnson might be able to charge--possibly even more--for their Hepatitis C drug.

  • Mad Mail: Throw Merck Out With Schering? Wednesday, 3 Sep 2008 | 6:36 PM ET

    Plus, Cramer make the call on IBM, CSX, Celgene and more.

  • Putting Cramer in Context Friday, 15 Aug 2008 | 7:18 PM ET

    This is how you balance Mad Money stock picks with your own portfolio.

  • Speculating on Alexion Pharma Thursday, 14 Aug 2008 | 11:44 PM ET

    This biotech sells its treatment to a niche clientele for big money.

  • Worst House, Best Neighborhood Wednesday, 13 Aug 2008 | 11:09 PM ET

    Vertex Pharma is lagging its peers. But biotech is so good right now, it might not matter.

  • Regulatory "Risky Business" for Pharma & Biotech Monday, 28 Apr 2008 | 11:56 AM ET
    Risky Business

    It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.

  • Schering Plows Through Vytorin Firestorm Wednesday, 23 Apr 2008 | 12:57 PM ET

    Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...

  • Options Look to Hepatitis-C Payoff Thursday, 3 Apr 2008 | 9:40 AM ET

    Options activity is picking up in Johnson & Johnson stock. Why?

  • Vytorin Battle Pits Merck/Schering-Plough Vs Pfizer Tuesday, 1 Apr 2008 | 11:03 AM ET

    Given investor reaction to the Vytorin/Zetia news yesterday, you might draw the conclusion the huge cholesterol drug franchise might be doomed. Sure, analysts say, prescriptions and sales are gonna go down some more, but they're not going to zero.

  • Pops & Drops: Fortune Brands, Northwest... Monday, 31 Mar 2008 | 7:00 PM ET

    Following are the day’s biggest winners and losers. Find out why shares of Fortune Brands and Northwest Airlines popped while Thornburg Mortgage  and Cal-Maine Foods dropped.

  • Major Indices Teetering on Breaking Losing Streaks Monday, 31 Mar 2008 | 9:47 AM ET

    The Dow, S&P and Nasdaq are just points away from breaking their monthly losing streaks at 4 straight months of losses. Here's what they would need to rally today to have their first positive month since October:

  • Merck, Vertex MK-0457 Trials Halted on Heart Risk Tuesday, 20 Nov 2007 | 9:01 PM ET

    Vertex Pharmaceuticals said Merck & Co halted enrollment on trials of their investigational leukemia drug MK-0457 due to a potential heart safety issue in one patient.

  • Vertex In The "Vortex" Over Hepatitis C Test Results Friday, 2 Nov 2007 | 12:04 PM ET
    Vertex

    There's a flurry of selling going on this morning in shares of the biopharma Vertex Pharmaceuticals. Overnight the embargo lifted on the long awaited results of the company's mid-stage test on a new type of Hepatitis C drug. Two studies show that six months out 60% and 65% of patients had no detectable virus in their blood.

  • Biogen Idec: First Of A Biotech Buying Binge? Monday, 15 Oct 2007 | 12:52 PM ET

    For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.

  • Quarterly earnings reports and new drug trial data were some of the catalysts behind the most actively traded stocks on Wednesday.